Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kartos Therapeutics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is being processed by the distinct examiner in the distinct art unit. DOUGLAS M WILLIS is the busiest examiner for the portfolio, managing 1 busiest examiner pending action.
The 1 pending office action is the sole focus of the company's current prosecution in the Biotechnology & Pharmaceuticals sector. With the distinct examiner and the distinct art unit being the only ones involved, the administrative footprint is minimal. DOUGLAS M WILLIS is responsible for the busiest examiner pending action, meaning all current results depend on this official. This centralized structure allows for a direct and consistent approach to the pending matter at the USPTO. Practitioners should note that the absence of multiple art units simplifies the tracking of procedural deadlines. The specific art unit assignment suggests that the patent counsel should focus on precedents from that technical group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690554 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690554 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690554 | METHODS OF TREATING A CANCER OVEREXPRESSING ONE OR MORE BCL-2 FAMILY PROTEINS | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Mar 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKartos Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Douglas M Willis has the most, with 1 of Kartos Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
